EntreMed Contracts With Elan to Produce Panzem(R) Clinical Material

    ROCKVILLE, Md., July 13 /PRNewswire-FirstCall/ -- EntreMed, Inc.
 (Nasdaq:   ENMD), a clinical-stage biopharmaceutical company developing
 therapeutics primarily for the treatment of cancer, today announced that it
 has entered into a Clinical Supply Agreement with Elan Drug Delivery, Inc. to
 reformulate and manufacture EntreMed's Panzem(R) in an oral liquid product
 format.  This supply of reformulated Panzem(R) will support EntreMed's
 clinical oncology program that is planned to begin in early 2005.  Elan is
 manufacturing the reformulated Panzem(R) using its proprietary NanoCrystal(R)
 technology that enhances product bioavailability and absorption and produces
 particles that are fifty times smaller than conventional processes.  A number
 of products using NanoCrystal(R) technology have been commercialized
 successfully, including Wyeth's Rapmune(R) and Merck's Emend(R).
     (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
     EntreMed President and Chief Executive Officer James S. Burns commented,
 "We remain on schedule with our plan to initiate clinical trials with
 reformulated Panzem(R) in cancer patients in early 2005.  Using Elan's
 NanoCrystal(R) technology, we believe we have developed a robust formulation
 of Panzem(R) that will improve product bioavailability and provide patients
 with a convenient orally administrated liquid product.  EntreMed and Elan are
 working together closely to ensure that internal timelines continue to be
     About EntreMed
     EntreMed, Inc. (Nasdaq:   ENMD) is a clinical-stage biopharmaceutical
 company developing therapeutic candidates primarily for the treatment of
 cancer.  Panzem(R), the Company's lead drug candidate, is currently in
 clinical trials for cancer, as well as in discovery and preclinical
 development for indications outside of oncology.  EntreMed's research and
 development programs are designed to identify new chemical entities by
 understanding the interrelationships of cell cycle regulation, inflammation,
 coagulation and angiogenesis -- processes vital to the treatment of multiple
 diseases, including cancer.  These programs have led to the identification of
 new therapeutic targets such as inhibition of the tissue factor pathway and
 the proteinase-activated receptor-2 (PAR-2). Based on these targets, EntreMed
 scientists are designing additional drug candidates for in-house development
 or partnering opportunities.  For further information, visit the Company's
 website at http://www.entremed.com.
     About Elan's NanoCrystal Technology
     NanoCrystal technology may enhance the clinical performance of poorly
 water-soluble drugs by transforming them into nanometer-sized particles.  An
 increasing number of the drug candidates synthesized each year by
 pharmaceutical companies are poorly water-soluble.  Many of these potentially
 innovative drug candidates are often abandoned because of poor pharmacokinetic
 properties including absorption, distribution, metabolism, and excretion.
 NanoCrystal technology has the potential to rescue a significant percentage of
 these chemical compounds.  The drug in nano-form can be incorporated into
 common dosage forms, including tablets, capsules, inhalation devices, sterile
 forms for injection, with the potential for substantial improvements to
 clinical performance.  There are currently two pharmaceutical products that
 have been commercialized incorporating NanoCrystal technology, with several
 additional product launches anticipated over the next two years.  The
 NanoCrystal technology is protected by 85 issued U.S. patents and 48 pending
 patents.  More information about Elan's technologies including its NanoCrystal
 technology is available at http://www.elan.com/DrugDelivery
     About Elan
     Elan Drug Delivery Inc. is an indirect wholly-owned subsidiary of Elan
 Corporation, plc, which is a neuroscience-based biotechnology company that is
 focused on discovering, developing, manufacturing and marketing advanced
 therapies in neurology, autoimmune diseases, and severe pain. Elan (NYSE:   ELN)
 shares trade on the New York, London and Dublin Stock Exchanges. For further
 information, visit the Company's website at http://www.elan.com.
     Forward Looking Statements
     This release contains, and other statements that EntreMed may make may
 contain, forward-looking statements within the meaning of the Private
 Securities Litigation Reform Act with respect to the outlook for expectations
 for future financial or business performance, strategies, expectations and
 goals. Forward-looking statements are typically identified by words or phrases
 such as "believe," "feel," "expect," "anticipate," "intend," "outlook,"
 "estimate," "target," "assume," "goal," "objective," "plan," "remain," "seek,"
 "trend," and variations of such words and similar expressions, or future or
 conditional verbs such as "will," "would," "should," "could," "might," "can,"
 "may," or similar expressions.  Forward-looking statements are subject to
 numerous assumptions, risks and uncertainties, which change over time.
 Forward-looking statements speak only as of the date they are made, and
 EntreMed assumes no duty to update forward-looking statements.  Actual results
 could differ materially from those currently anticipated due to a number of
 factors, including those set forth in EntreMed's Securities and Exchange
 Commission filings under "Risk Factors," including risks relating to
 EntreMed's need for additional capital and the uncertainty of additional
 funding; the early-stage products under development; uncertainties relating to
 clinical trials; our success in optimizing Panzem(R) for further clinical
 development; dependence on third parties; future capital needs; and risks
 relating to the commercialization, if any, of the Company's proposed products
 (such as marketing, safety, regulatory, patent, product liability, supply,
 competition and other risks).
     CONTACT:  Amy Finan, Senior Director, Corporate, Communications & Industry
 Relations of EntreMed, Inc., +1-240-864-2640

SOURCE EntreMed, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.